NASDAQ:MAXY - Maxygen Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Maxygen, Inc. (Maxygen) is a biotechnology company focused on the development of its MAXY-G34 product candidate. MAXY-G34 is a pegylated, granulocyte colony stimulating factor (G-CSF), for the treatment of chemotherapy-induced neutropenia and acute radiation syndrome (ARS). On May 16, 2011, Astellas Pharma Inc. (Astellas) acquired the Company's interests in Perseid Therapeutics LLC, the Company's former subsidiary, which included all of the Company's research and development operations. As a result of the transaction, the Company has reclassified the operating results of Perseid, as well as any related business activities, to discontinued operations. The Company's wholly owned subsidiaries include Maxygen Holdings (U.S.), Inc., Maxygen ApS and Maxygen Holdings, Inc., and its majority owned subsidiary, Maxygen Holdings LLC.

Receive MAXY News and Ratings via Email

Sign-up to receive the latest news and ratings for MAXY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:MAXY
CUSIP57777610
Phone+1-650-2412292

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Maxygen (NASDAQ:MAXY) Frequently Asked Questions

What is Maxygen's stock symbol?

Maxygen trades on the NASDAQ under the ticker symbol "MAXY."

Has Maxygen been receiving favorable news coverage?

News articles about MAXY stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Maxygen earned a news sentiment score of -1.4 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days.

How do I buy shares of Maxygen?

Shares of MAXY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Maxygen's official website?

The official website for Maxygen is https://www.maxygen.com/.

How can I contact Maxygen?

Maxygen's mailing address is 725 San Aleso Ave Ste 2, SUNNYVALE, CA 94085-1400, United States. The biotechnology company can be reached via phone at +1-650-2412292.


MarketBeat Community Rating for Maxygen (NASDAQ MAXY)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  26 (Vote Outperform)
Underperform Votes:  42 (Vote Underperform)
Total Votes:  68
MarketBeat's community ratings are surveys of what our community members think about Maxygen and other stocks. Vote "Outperform" if you believe MAXY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MAXY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/26/2019 by MarketBeat.com Staff

Featured Article: Price-Sales Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel